Edition:
United States

Biogaia AB (BIOGb.ST)

BIOGb.ST on Stockholm Stock Exchange

425.00SEK
18 May 2018
Change (% chg)

-- (--)
Prev Close
425.00kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
26,332
52-wk High
459.50kr
52-wk Low
278.50kr

Chart for

About

Biogaia AB is a Sweden-based company engaged in the development and sell of probiotic products, primarily based on the Lactobacillus reuteri bacteria. The Company’s activities are divided into three segments: Finished consumer products, which distributes tablets, drops, Oral Rehydration Solutions (ORSs), and oral health... (more)

Overall

Beta: 0.70
Market Cap(Mil.): kr6,985.21
Shares Outstanding(Mil.): 16.60
Dividend: 4.31
Yield (%): 2.12

Financials

  BIOGb.ST Industry Sector
P/E (TTM): 40.74 19.73 38.77
EPS (TTM): 10.43 -- --
ROI: 37.46 10.88 46.42
ROE: 37.50 14.41 54.22

BRIEF-Biogaia Q1 operating profit roughly unchanged yr/yr

* BIOGAIA AB Q1 OPERATING PROFIT AMOUNTED TO SEK 56.2 MILLION (56.1) Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Apr 25 2018

BRIEF-Biogaia increases stake in MetaboGen to 62 pct

* Has decided to acquire additional shares in the associated company MetaboGen AB and is now investing SEK 11.7 million in shares in the company.

Apr 06 2018

BRIEF-Biogaia partners with Dr Reddy's for India launch of protectis drops

* BIOGAIA HAS ENTERED INTO A PARTNERSHIP WITH DR. REDDY’S LABORATORIES FOR THE MARKETING AND DISTRIBUTION OF BIOGAIA PROTECTIS DROPS IN THE INDIAN MARKET

Mar 23 2018

BRIEF-Biogaia Q4 profit rises, proposes extra dividend

* Q4 NET SALES AMOUNTED TO SEK 170.1 MILLION VS YR-AGO 138.8 MILLION, AN INCREASE OF 23% (EXCLUDING FOREIGN EXCHANGE EFFECTS, 27%)

Feb 08 2018

BRIEF-Biogaia signs deal with Abbott to launch probiotic in China

* SAYS HAS SIGNED AN EXCLUSIVE AGREEMENT WITH ABBOTT FOR RIGHTS TO COMMERCIALIZE BIOGAIA PROTECTIS TABS IN CHINA

Jan 18 2018

Earnings vs. Estimates